A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (n = 60) or the placebo (n = 60) f...

全面介绍

书目详细资料
Main Authors: Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani
格式: 文件
语言:English
出版: Frontiers Media S.A. 2022-07-01
丛编:Frontiers in Medicine
主题:
sitagliptin
NAFLD
clinical trial design
fibrosis scores
liver enzymes
在线阅读:https://www.frontiersin.org/articles/10.3389/fmed.2022.937554/full

因特网

https://www.frontiersin.org/articles/10.3389/fmed.2022.937554/full

相似书籍